The Respiratory Syncytial Virus Vaccine Landscape: Lessons From the Graveyard and Promising Candidates
This article, published in The Lancet Infectious Diseases, highlights promising new approaches to respiratory syncytial virus (RSV) vaccine design and provides a comprehensive overview of the 19 RSV vaccine candidates and monoclonal antibodies in clinical development. It also provides information on the target populations for RSV interventions, vaccine strategies, and lessons learned from late-phase RSV vaccine clinical trial failures to help inform future vaccine development. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Mazur NI, Higgins D, Nunes MC, et al.
» Visit web page (English)
(Located at www.thelancet.com)
Citation: Mazur NI, Higgins D, Nunes MC, et al. The Respiratory Syncytial Virus Vaccine Landscape: Lessons From the Graveyard and Promising Candidates. The Lancet Infectious Diseases. 2018;18(10):e295-e311.
Resource types: Peer-reviewed journal
Diseases/vaccines: Respiratory syncytial virus (RSV)